DNP-002

N/A

Report date: 2024/11/15 16:05:53

Base Information

Drug NameDNP-002
Drug Alias NameDNP-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunostimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCarcinoembryonic antigen related cell adhesion molecule 6 inhibitors
TargetsCarcinoembryonic antigen related cell adhesion molecule 6
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDinona
China Registration ClassN/A

Develop Information

Active CompaniesKumho HT IncDinona
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A